News By: Gary Cramer

While new regulations and incentives for sponsors may help, no negative actions have been taken in the FDA’s oncology review divisions in cases of sponsor failure to conduct more diverse trials, and vague diversity guidance continues to raise concerns.

The words data, metrics, reporting, analytics, and insights are frequently used interchangeably by organizations while assessing a meeting’s results to inform future meeting planning, but the distinctions between them are important.

There is clinical trials industry momentum for adopting new methods for the capture of intentionally collected data at the point of care, leveraging the electronic health record.

Presenting an overview of challenges faced in early-phase studies and the corresponding technologies that help overcome and eliminate these issues.

"As 2022 comes to a close, it’s exciting to look back at how ACRP continues to adapt and meet or exceed the needs and expectations of clinical research professionals around the world."